The Federal Antimonopoly Service (FAS) of Russia has approved the price for the first domestic generic of the anticancer drug Alecensa (alectinib), originally developed by Swiss company Roche. The generic, Alectinib-Amedart, will be 40% cheaper than the reference (originator) drug, according to a statement from the FAS press service.
“The price for one 150 mg generic capsule has been set at 572 rubles, while the cost of one capsule of the reference drug in the same dosage is 954 rubles,” the statement said.
According to the FAS, approving the generic’s price will “increase availability and expand the choice of such drugs for citizens after the patent on the original has expired.”
Alectinib is included in Russia’s list of Vital and Essential Drugs (VED). The Alectinib-Amedart capsules are manufactured by Amedart, a resident of the Technopolis Moscow Special Economic Zone, with pharmaceutical substances produced by Amedart itself and by India’s Hetero Labs.
